HomeMarketsStories

    Market

    Amycretin receives FDA Fast Track designation by end of 2025?

    3
    Novo Nordisk
    Resolution / Starting Odds

    Yes • 50%

    No • 50%

    FDA announcements and Novo Nordisk press releases

    Story

    Novo Nordisk's Amycretin Achieves 22% Weight Loss in Early Trial, Shares Jump 11%

    Novo Nordisk's Amycretin Achieves 22% Weight Loss in Early Trial, Shares Jump 11%

    Jan 24, 2025, 11:05 AM

    Novo Nordisk announced positive results from an early-stage clinical trial of its next-generation experimental obesity drug, amycretin. In the phase 1b/2a trial involving 125 participants with overweight or obesity, those treated with amycretin achieved up to 22% weight loss after 36 weeks. Amycretin is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk's shares surged by as much as 11%, the most in a month.

    View original story

    Similar markets

    Will amycretin receive FDA Breakthrough Therapy designation by end of 2025?

    Will amycretin receive FDA Breakthrough Therapy designation by end of 2025?

    Yes • 50%

    No • 50%

    Amycretin enters Phase 3 trials by mid-2026?

    Amycretin enters Phase 3 trials by mid-2026?

    No • 50%

    Yes • 50%

    FDA approval for Novo Nordisk's amycretin by end of 2025?

    FDA approval for Novo Nordisk's amycretin by end of 2025?

    No • 50%

    Yes • 50%

    Will HS-10535 receive FDA Fast Track designation by end of 2025?

    Will HS-10535 receive FDA Fast Track designation by end of 2025?

    Yes • 50%

    No • 50%

    Outcome of amycretin Phase 2 trials by end of 2025?

    Outcome of amycretin Phase 2 trials by end of 2025?

    Negative results • 25%

    Mixed results • 25%

    Positive results • 25%

    Trial halted • 25%

    Will SHR-4849 receive FDA Breakthrough Therapy designation by end of 2025?

    Will SHR-4849 receive FDA Breakthrough Therapy designation by end of 2025?

    No • 50%

    Yes • 50%

    Will IDRX-42 receive FDA Fast Track designation by mid-2025?

    Will IDRX-42 receive FDA Fast Track designation by mid-2025?

    No • 50%

    Yes • 50%

    Crenessity to receive FDA Breakthrough Therapy designation for another condition by end of 2025?

    Crenessity to receive FDA Breakthrough Therapy designation for another condition by end of 2025?

    No • 50%

    Yes • 50%

    Will Novo Nordisk's amycretin advance to phase 3 trials by end of 2025?

    Will Novo Nordisk's amycretin advance to phase 3 trials by end of 2025?

    Yes • 50%

    No • 50%

    Merck's HS-10535 FDA Approval by End of 2025?

    Merck's HS-10535 FDA Approval by End of 2025?

    Yes • 50%

    No • 50%

    Will IDEAYA receive FDA Fast Track for SHR-4849 in 2025?

    Will IDEAYA receive FDA Fast Track for SHR-4849 in 2025?

    No • 50%

    Yes • 50%

    Amycretin market launch date in the US?

    Amycretin market launch date in the US?

    2027 • 25%

    2029 or later • 25%

    2028 • 25%

    2026 • 25%

    Markets based on same story

    Loading...
    Looking for markets...

    Show all

    Amycretin advances to phase 3 trials by end of 2025?

    Amycretin advances to phase 3 trials by end of 2025?

    No • 50%

    Yes • 50%

    Novo Nordisk shares increase by over 20% by end of Q2 2025?

    Novo Nordisk shares increase by over 20% by end of Q2 2025?

    No • 50%

    Yes • 50%

    Main competitor to Novo Nordisk in obesity drug market by end of 2025?

    Main competitor to Novo Nordisk in obesity drug market by end of 2025?

    Pfizer • 25%

    Roche • 25%

    Eli Lilly • 25%

    Other • 25%

    Peak share price of Novo Nordisk in 2025?

    Peak share price of Novo Nordisk in 2025?

    Above $1100 • 25%

    Below $900 • 25%

    $900 to $1000 • 25%

    $1000 to $1100 • 25%